000148920 001__ 148920
000148920 005__ 20240229120021.0
000148920 0247_ $$2doi$$a10.1177/1758835919887667
000148920 0247_ $$2pmid$$apmid:31897090
000148920 0247_ $$2pmc$$apmc:PMC6918487
000148920 0247_ $$2ISSN$$a1758-8340
000148920 0247_ $$2ISSN$$a1758-8359
000148920 0247_ $$2altmetric$$aaltmetric:124363361
000148920 037__ $$aDKFZ-2020-00078
000148920 041__ $$aeng
000148920 082__ $$a610
000148920 1001_ $$0P:(DE-He78)a44ef83e4213638f939d4e35a3c52d34$$aGlas, Martin$$b0
000148920 245__ $$aRegorafenib in glioblastoma recurrence: how to deal with conflicting 'real-life' experiences?
000148920 260__ $$aThousand Oaks, Calif.$$bSage$$c2019
000148920 3367_ $$2DRIVER$$aarticle
000148920 3367_ $$2DataCite$$aOutput Types/Journal article
000148920 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1581516612_31356$$xLetter
000148920 3367_ $$2BibTeX$$aARTICLE
000148920 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148920 3367_ $$00$$2EndNote$$aJournal Article
000148920 500__ $$aEAL401LAL401
000148920 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000148920 588__ $$aDataset connected to CrossRef, PubMed,
000148920 7001_ $$0P:(DE-He78)e6bbfbfebf0444562d54516969dde039$$aKebir, Sied$$b1
000148920 773__ $$0PERI:(DE-600)2503443-1$$a10.1177/1758835919887667$$gVol. 11, p. 175883591988766 -$$p175883591988766 -$$tTherapeutic advances in medical oncology$$v11$$x1758-8359$$y2019
000148920 909CO $$ooai:inrepo02.dkfz.de:148920$$pVDB
000148920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a44ef83e4213638f939d4e35a3c52d34$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000148920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e6bbfbfebf0444562d54516969dde039$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000148920 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000148920 9141_ $$y2019
000148920 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000148920 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000148920 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTHER ADV MED ONCOL : 2017
000148920 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148920 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148920 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000148920 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000148920 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000148920 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000148920 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ
000148920 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148920 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148920 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148920 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bTHER ADV MED ONCOL : 2017
000148920 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x0
000148920 980__ $$ajournal
000148920 980__ $$aVDB
000148920 980__ $$aI:(DE-He78)L401-20160331
000148920 980__ $$aUNRESTRICTED